3,850 results match your criteria Oral Malignant Melanoma


Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine.

Support Care Cancer 2019 Feb 14. Epub 2019 Feb 14.

Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

The most common adverse event (AE) of dabrafenib and trametinib (DT) is pyrexia, which has been reported to occur in up to 71% of patients. Pyrexia resulted in therapy discontinuation in up to 26% of patients that otherwise were benefiting from the treatment. Little is known about the pathogenesis and optimal management of this common AE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-4654-2DOI Listing
February 2019

A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma.

Vet Sci 2019 Feb 12;6(1). Epub 2019 Feb 12.

Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, Grafton, MA 01536, USA.

In dogs, melanomas are relatively common tumors and the most common form of oral malignancy. Biological behavior is highly variable, usually aggressive, and frequently metastatic, with reported survival times of three months for oral or mucosal melanomas in advanced disease stages. Classical clinical management remains challenging; thus, novel and more efficacious treatment strategies are needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/vetsci6010015DOI Listing
February 2019

Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA Expression.

Cancers (Basel) 2019 Feb 11;11(2). Epub 2019 Feb 11.

Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan.

Melanoma is a highly aggressive cancer with high mortality in advanced stages.Metformin is an oral biguanide drug used for diabetes and has demonstrated positive effects oncancer prevention and treatment. Herein, we found that metformin significantly suppressedmelanoma cancer cell motility and growth through inducing cell cycle arrest at the G2/M phase andpromoting cell apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020209DOI Listing
February 2019

Oral mycosis fungoides with CD30 large cell transformation successfully treated with brentuximab vedotin.

JAAD Case Rep 2019 Feb 30;5(2):180-183. Epub 2019 Jan 30.

Georgetown University School of Medicine, Department of Dermatology, Washington, DC.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525126183034
Publisher Site
http://dx.doi.org/10.1016/j.jdcr.2018.11.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357896PMC
February 2019
2 Reads

IFN regulatory factor-8 expression in macrophages governs an antimetastatic program.

JCI Insight 2019 Feb 7;4(3). Epub 2019 Feb 7.

Department of Immunology.

High macrophage infiltration in cancer is associated with reduced survival in animal models and in patients. This reflects a shift in the macrophage response from a tumor-suppressive to tumor-supportive program governed by transcriptional events regulated by the inflammatory milieu. Although several transcription factors are known to drive a prometastatic program, those that govern an antimetastatic program are less understood. Read More

View Article

Download full-text PDF

Source
https://insight.jci.org/articles/view/124267
Publisher Site
http://dx.doi.org/10.1172/jci.insight.124267DOI Listing
February 2019
2 Reads

Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?

Methods Mol Biol 2019 ;1866:311-322

AntiCancer, Inc., San Diego, CA, USA.

The elevated methionine (MET) requirement of cancer cells is termed MET dependence and is possibly the only known general metabolic defect in cancer. Targeting MET by recombinant methioninase (rMETase) can arrest the growth of cancer cells in vitro and in vivo due to their elevated requirement for MET. rMETase can also potentiate chemotherapy drugs active in S phase due to the selective arrest of cancer cells in S/G phase during MET restriction (MR). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-4939-8796-2_24
Publisher Site
http://dx.doi.org/10.1007/978-1-4939-8796-2_24DOI Listing
January 2019
3 Reads

Canine oral primary melanoma cells exhibit shift to mesenchymal phenotype and phagocytic behaviour.

Vet Comp Oncol 2019 Feb 4. Epub 2019 Feb 4.

Research Group Oncology (RGO), Equine Surgery, Department for Small Animals and Horses, University of Veterinary Medicine, Vienna, Austria.

Canine oral malignant melanoma (COMM) is a potentially lethal cancer disease. We established primary cell lines from mostly amelanotic primary COMM and metastases and assessed lesions and derived cells for Melan A, PNL2 and CD146 expression. Then, migration and invasion of CD146-enriched versus -depleted COMM cells were analysed. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/vco.12464
Publisher Site
http://dx.doi.org/10.1111/vco.12464DOI Listing
February 2019
4 Reads

Transducin-like enhancer of split 3 regulates proliferation of melanoma cells via histone deacetylase activity.

Oncotarget 2019 Jan 8;10(3):404-414. Epub 2019 Jan 8.

Division of Molecular Signaling and Biochemistry, Department of Health Improvement, Kyushu Dental University, Kitakyushu, Fukuoka, Japan.

Melanoma, one of the most aggressive neoplasms, is characterized by rapid cell proliferation. Transducin-like Enhancer of Split (TLE) is an important regulator of cell proliferation via Histone deacetylase (HDAC) recruitment. Given that HDAC activity is associated with melanoma progression, we examined the relationship between TLE3, a TLE family member, and melanoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349449PMC
January 2019

Association Between Cancer Incidence and Mortality in Web-Based Data in China: Infodemiology Study.

J Med Internet Res 2019 Jan 29;21(1):e10677. Epub 2019 Jan 29.

School of Public Health, Tianjin Medical University, Tianjin, China.

Background: Cancer poses a serious threat to the health of Chinese people, resulting in a major challenge for public health work. Today, people can obtain relevant information from not only medical workers in hospitals, but also the internet in any place in real-time. Search behaviors can reflect a population's awareness of cancer from a completely new perspective, which could be driven by the underlying cancer epidemiology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2196/10677DOI Listing
January 2019
2 Reads
3.428 Impact Factor

Clinicopathological study of malignant melanoma in a regional cancer center.

Indian J Cancer 2018 Jul-Sep;55(3):292-296

Department of Pathology, A.H. Regional Cancer Centre, Cuttack, Odisha, India.

Background: : Malignant melanoma is a tumor of melanocytic origin. Although uncommon in India as compared with the west, its prevalence is increasing.

Objectives: To document the pattern of clinicopathological features of malignant melanoma cases attending in a regional cancer center in eastern India. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijc.IJC_612_17DOI Listing
January 2019
1 Read

Black and Brown Oro-facial Mucocutaneous Neoplasms.

Authors:
Easwar Natarajan

Head Neck Pathol 2019 Jan 29. Epub 2019 Jan 29.

Section of Oral and Maxillofacial Pathology, University of Connecticut Health Center, 263 Farmington Ave, MC-0925, Farmington, CT, 06030, USA.

Black and brown-colored mucocutaneous lesions present a differential diagnostic challenge, with malignant melanoma being the primary clinical concern. The vast majority of pigmented lesions in the head and neck region are the result of benign, reactive factors such as post-inflammatory melanosis. However, it is not uncommon to discover a range of muco-cutaneous black and brown neoplasms in the oro-facial area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12105-019-01008-2DOI Listing
January 2019
2 Reads

Cannabinoids as a Potential New and Novel Treatment for Melanoma: A Pilot Study in a Murine Model.

J Surg Res 2019 Mar 30;235:210-215. Epub 2018 Oct 30.

Department of Oral Biology/Dental College of Georgia, Augusta University Medical Center, Augusta, Georgia; Division of Plastic Surgery/Medical College of Georgia, Department of Surgery, Augusta University Medical Center, Augusta, Georgia.

Background: Malignant melanoma is a complex malignancy with significant morbidity and mortality. The incidence continues to rise, and despite advances in treatment, the prognosis is poor. Thus, it is necessary to develop novel strategies to treat this aggressive cancer. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00224804183062
Publisher Site
http://dx.doi.org/10.1016/j.jss.2018.08.055DOI Listing
March 2019
2 Reads

Loss of SLC25A11 causes suppression of NSCLC and melanoma tumor formation.

EBioMedicine 2019 Jan 24. Epub 2019 Jan 24.

Tumor Microenvironment Research Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Republic of Korea. Electronic address:

Background: Fast growing cancer cells require greater amounts of ATP than normal cells. Although glycolysis was suggested as a source of anabolic metabolism based on lactate production, the main source of ATP to support cancer cell metabolism remains unidentified.

Methods: We have proposed that the oxoglutarate carrier SLC25A11 is important for ATP production in cancer by NADH transportation from the cytosol to mitochondria as a malate. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523964193004
Publisher Site
http://dx.doi.org/10.1016/j.ebiom.2019.01.036DOI Listing
January 2019
2 Reads

A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma.

Am J Case Rep 2019 Jan 25;20:106-110. Epub 2019 Jan 25.

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Fukuoka, Japan.

BACKGROUND Ipilimumab is a therapeutic human monoclonal antibody that targets the T-cell inhibitory molecule, cytotoxic T-lymphocyte antigen-4 (CTLA-4), and is classified as an immune checkpoint inhibitor that has been shown to improve prognosis in patients with advanced melanoma. However, several immune-related adverse events have been reported to be associated with ipilimumab Treatment. A case of acute exacerbation of chronic adrenal insufficiency is presented that highlights that glucocorticoid dosage for patients undergoing steroid treatment at the time of ipilimumab treatment has yet to be established. Read More

View Article

Download full-text PDF

Source
https://www.amjcaserep.com/abstract/index/idArt/913021
Publisher Site
http://dx.doi.org/10.12659/AJCR.913021DOI Listing
January 2019
2 Reads

Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.

Dermatol Online J 2018 Aug 15;24(8). Epub 2018 Aug 15.

Department of Dermatology, Hospital Universitario Fundacion Alcorcon, Madrid.

Vemurafenib, a kinase inhibitor that targets tumors with the BRAF V600E mutation, is a promising option for unresectable or metastatic melanoma. Cutaneous side-effects have been reported including alopecia, photosensitivity, squamous cell carcinoma, keratoacanthomas, keratosis pilaris-like eruption, and palmoplantar hyperkeratosis. Acneiform eruptions have been reported in 3%-6% of the patients treated with BRAF inhibitors,and 5 cases are described in the literature. Read More

View Article

Download full-text PDF

Source
August 2018
2 Reads

Feasibility of carbon-ion radiotherapy for oral non-squamous cell carcinomas.

Head Neck 2019 Jan 24. Epub 2019 Jan 24.

Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.

Background: This study evaluated carbon-ion radiotherapy (C-ion RT) for oral non-squamous cell carcinomas (non-SCC).

Methods: We retrospectively obtained data from 74 patients who underwent C-ion RT for oral malignancies between April 1997 and March 2016. The C-ion RT was administered in 16 fractions at a total dose of 57. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hed.25618
Publisher Site
http://dx.doi.org/10.1002/hed.25618DOI Listing
January 2019
2 Reads

Oral Administration of Fermented Papaya (FPP) Controls the Growth of a Murine Melanoma through the In Vivo Induction of a Natural Antioxidant Response.

Cancers (Basel) 2019 Jan 20;11(1). Epub 2019 Jan 20.

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.

Prolonged oxidative stress may play a key role in tumor development. Antioxidant molecules are contained in many foods and seem to have a potential role in future anti-tumor strategies. Among the natural antioxidants the beneficial effect of Fermented Papaya (FPP) is well known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11010118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356895PMC
January 2019

Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma.

Nat Commun 2019 01 21;10(1):353. Epub 2019 Jan 21.

Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.

Mucosal melanoma is a rare and poorly characterized subtype of human melanoma. Here we perform a cross-species analysis by sequencing tumor-germline pairs from 46 primary human muscosal, 65 primary canine oral and 28 primary equine melanoma cases from mucosal sites. Analysis of these data reveals recurrently mutated driver genes shared between species such as NRAS, FAT4, PTPRJ, TP53 and PTEN, and pathogenic germline alleles of BRCA1, BRCA2 and TP53. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-08081-1
Publisher Site
http://dx.doi.org/10.1038/s41467-018-08081-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341101PMC
January 2019
4 Reads

FAK inhibition reduces metastasis of α4 integrin-expressing melanoma to lymph nodes by targeting lymphatic VCAM-1 expression.

Biochem Biophys Res Commun 2019 Feb 17;509(4):1034-1040. Epub 2019 Jan 17.

Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL, 36688, United States. Electronic address:

Malignant melanoma typically metastasizes to lymph nodes (LNs) as a primary or in-transit lesion before secondary metastasis occurs, and LN biopsy is a common procedure to diagnose melanoma progression. Since cancer metastasis is a complex process where various interactions between tumor cells and the stroma play key roles in establishing metastatic lesions, the exact mechanisms underlying melanoma metastasis to LNs remains unknown. It has been known that focal adhesion kinase (FAK) activity promotes the expression of proinflammatory vascular cell adhesion molecule-1 (VCAM-1). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0006291X193005
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2019.01.050DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350924PMC
February 2019
5 Reads

Identification of dysregulated microRNAs in canine malignant melanoma.

Oncol Lett 2019 Jan 12;17(1):1080-1088. Epub 2018 Nov 12.

Department of Clinical Veterinary Science, United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi 753-8511, Japan.

Inhibiting aberrantly upregulated microRNAs (miR/miRNAs) has emerged as a novel focus for therapeutic intervention in human melanoma. Thus, identifying upregulated miRNAs is essential for identifying additional melanoma-associated therapeutic targets. In the present study, microarray-based miRNA profiling of canine malignant melanoma (CMM) tissue obtained from the oral cavity was performed and differential expression was confirmed by a reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2018.9692
Publisher Site
http://dx.doi.org/10.3892/ol.2018.9692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313064PMC
January 2019
2 Reads
0.987 Impact Factor

A rare case of oral melanoacanthoma.

J Oral Maxillofac Pathol 2018 Sep-Dec;22(3):410-412

Department of Oral Pathology and Microbiology, Sardar Patel Postgraduate Institute of Dental and Medical Sciences, Lucknow, Uttar Pradesh, India.

Oral melanoacanthoma is a rare, pigmented lesion which brings suspicion of a malignancy with its sudden appearance and rapid growth. It is characterized clinically as a brown-black lesion and histologically it shows acanthosis of the superficial epithelium and proliferation of dendritic melanocytes. Due to their unusual clinical pattern, biopsy is mandatory to rule out malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jomfp.JOMFP_96_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306582PMC
January 2019
6 Reads

Genetic and environmental risk factors for vitiligo and melanoma in Pura Raza Español horses.

Equine Vet J 2019 Jan 9. Epub 2019 Jan 9.

Department of Agro-Forestry Sciences, ETSIA, University of Seville, Seville, Spain.

Background: Vitiligo and melanoma are relatively common disorders in grey Pura Raza Español horses and other horse breeds with grey-coloured coats.

Objectives: To determine the breed prevalence, environmental risks factors and estimate the genetic parameters for vitiligo and melanoma in Pura Raza Español horses.

Study Design: Retrospective cohort study. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/evj.13067
Publisher Site
http://dx.doi.org/10.1111/evj.13067DOI Listing
January 2019
10 Reads

Improving cancer-specific outcomes in solid organ transplant recipients: Where to begin?

Cancer 2019 Jan 9. Epub 2019 Jan 9.

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.

In an article published in this issue of Cancer, D'Arcy et al link the incidence of cancer among recipients of solid organ transplantation (SOT) in the Scientific Registry of Transplant Recipients with data from regional and statewide cancer registries to examine cancer-specific mortality for common malignancies in SOT recipients. This analysis helps to illuminate the role of immune surveillance across a broad range of malignancies and compares the incidence of cancers due to virally mediated oncogenesis (lymphoma, squamous cell carcinoma of the aerodigestive epithelium, and hepatitis-induced liver cancer) with the incidence of other malignancies. The authors' central finding is that cancer-specific mortality is significantly increased in SOT recipients in comparison with nontransplant recipients for multiple cancers, and the increased cancer incidence is not limited to the effects of viral oncogenesis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31963
Publisher Site
http://dx.doi.org/10.1002/cncr.31963DOI Listing
January 2019
10 Reads

Survival after a cancer diagnosis among solid organ transplant recipients in the United States.

Cancer 2019 Jan 9. Epub 2019 Jan 9.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.

Background: Transplant recipients have an elevated risk of cancer because of immunosuppressive medications used to prevent organ rejection, but to the authors' knowledge no study to date has comprehensively examined associations between transplantation status and mortality after a cancer diagnosis.

Methods: The authors assessed cases in the US general population (N=7,147,476) for 16 different cancer types as ascertained from 11 cancer registries. The presence of a solid organ transplant prior to diagnosis (N=11,416 cancer cases) was identified through linkage with the national transplantation registry (1987-2014). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31782
Publisher Site
http://dx.doi.org/10.1002/cncr.31782DOI Listing
January 2019
7 Reads
4.889 Impact Factor

Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis.

Bone Res 2019 3;7. Epub 2019 Jan 3.

1Department of Immunology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo Japan.

Bone is one of the preferred sites for the metastasis of malignant tumours, such as breast cancer, lung cancer and malignant melanoma. Tumour cells colonizing bone have the capacity to induce the expression of receptor activator of nuclear factor-κB ligand (RANKL), which promotes osteoclast differentiation and activation. Tumour-induced osteoclastic bone resorption leads to a vicious cycle between tumours and bone cells that fuels osteolytic tumour growth, causing bone pain and hypercalcaemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41413-018-0036-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315020PMC
January 2019
2 Reads

In Vitro and Clinical Studies of Gene Therapy with Recombinant Human Adenovirus-p53 Injection for Malignant Melanoma.

Hum Gene Ther Clin Dev 2019 Jan 31. Epub 2019 Jan 31.

1 State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases and Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, P.R. China.

Malignant melanoma is an aggressive tumor with high fatality rates and poor prognosis, mainly due to the lack of efficient treatment methods. The present study investigated the potential antitumor effects of recombinant adenovirus p53 (rAd-p53) on human malignant melanoma. The optimal viral titer on a human malignant melanoma (A-375) cell line was determined for the rAd-p53 treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/humc.2018.112DOI Listing
January 2019
3 Reads

c kit in oral mucosal melanoma.

J BUON 2018 Nov-Dec;23(6):1927-1928

Dept of Immunohistochemistry & Molecular Biology, 401 GAH, Athens, Greece.

View Article

Download full-text PDF

Source
January 2019

Tongue metastasis of cutaneous melanoma: Report of two cases and literature review.

J Clin Exp Dent 2018 Nov 1;10(11):e1130-e1134. Epub 2018 Nov 1.

DDS, MSc, PhD. Dental Oncology Service, Instituto do Câncer do Estado de São Paulo [ICESP], Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, Brazil.

Introduction: Malignant metastases to the oral cavity are rare and metastatic melanomas of the tongue are considered exceptionally uncommon, with less than 10 cases published in the English literature so far.

Case Reports: Two female patients in the 7th decade of life presented to our dental service with nodules in the tongue. Both patients had multiple metastases at the time of oral diagnosis and primary melanoma originated on the skin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4317/jced.54980DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311407PMC
November 2018
1 Read

A Rare Cause of Uveitis: Vemurafenib

Turk J Ophthalmol 2018 Dec;48(6):323-325

Çukurova University Faculty of Medicine, Department of Ophthalmology, Adana, Turkey

A 25-year-old female presented with a decrease of vision and redness in both eyes. She had a history of nodular melanoma in her right shoulder, which was excised surgically and she was under oral vemurafenib treatment. She was diagnosed with moderately severe bilateral panuveitis and hospitalized for systemic investigation and workup. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4274/tjo.95914DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330668PMC
December 2018
1 Read

BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.

Am J Dermatopathol 2018 Dec 21. Epub 2018 Dec 21.

Dermatology Department, Chelsea and Westminster, London, United Kingdom.

Cutaneous toxicities associated with BRAF inhibitor treatment in patients with metastatic melanoma have been well described. We present a rare association of granulomatous dermatitis in association with the BRAF inhibitor vemurafenib. Three patients with metastatic melanoma all presented with asymptomatic papular eruptions 8-21 months into vemurafenib therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001276DOI Listing
December 2018
1 Read

Erianin induces cell apoptosis through ERK pathway in human nasopharyngeal carcinoma.

Biomed Pharmacother 2018 Dec 23;111:262-269. Epub 2018 Dec 23.

Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan; Division of Thoracic Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung 402, Taiwan. Electronic address:

Background: Nasopharyngeal carcinoma (NPC) is one of the most common cancers in areas of Southeast Asia, such as Taiwan, and North Africa. The treatments of NPC, including radiotherapy and chemotherapy, were effective, but they also caused some severe side effects. Erianin, a natural product derived from Dendrobium, was proved to have anti-cancer effect in hepatoma, melanoma, non-small-cell lung carcinoma, myelogenous leukemia, breast cancer, and osteosarcoma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07533322183691
Publisher Site
http://dx.doi.org/10.1016/j.biopha.2018.12.081DOI Listing
December 2018
8 Reads

Significance of PD-L1 Expression in Tongue Cancer Development.

Int J Med Sci 2018 22;15(14):1723-1730. Epub 2018 Nov 22.

Department of Pathology, Saitama Medical University International Medical Center, Saitama, Japan.

: Immunohistochemistry of PD-L1 has been recently established as a surrogate method to predict if immunotherapy targeting PD-L1/PD-1 has a significant effect on suppression of cancers such as lung non-small cell carcinoma, melanoma, and renal cell carcinoma. Here we performed immunohistochemistry for PD-L1 expression in squamous cell carcinoma (SCC) of the tongue to investigate the potential correlation between PD-L1 expression and clinicopathological factors and whether PD-L1 expression would be associated with prognosis. Tissue microarray cores of paraffin-embedded blocks from 135 cases with surgically resected tongue SCC were immunohistochemically analysed for PD-L1 expression. Read More

View Article

Download full-text PDF

Source
http://www.medsci.org/v15p1723.htm
Publisher Site
http://dx.doi.org/10.7150/ijms.27860DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299404PMC
November 2018
12 Reads

Overexpression of absent in melanoma 2 in oral squamous cell carcinoma contributes to tumor progression.

Biochem Biophys Res Commun 2019 Jan 23;509(1):82-88. Epub 2018 Dec 23.

Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki, Japan. Electronic address:

We had previously reported that in addition to p53 inactivation, overexpression of the DNA sensor protein-absent in melanoma 2 (AIM2)-contributes to tumorigenesis of oral squamous cell carcinoma (OSCC). Given that AIM2 is highly expressed in the OSCC tumors from patients with metastasis, we investigated whether AIM2 expression contributes to the progression of OSCC metastasis. In in vitro assays using OSCC cell lines, the high migration and invasion capacity of OSCC cells were dependent on the increased expression of AIM2, resulting in enhanced epithelial-mesenchymal transition (EMT), with EMT-related gene expression. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0006291X183270
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2018.12.066DOI Listing
January 2019
5 Reads

Skin Cancer Prevention: A Review of Current Oral Options Complementary to Sunscreens

J Drugs Dermatol 2018 Dec;17(12):1266-1271

The incidence of non-melanoma skin cancer (NMSC) is dramatically increasing worldwide, despite the increased use of improved sunscreens. In 2014, the Surgeon General estimated that 2.2 to 5. Read More

View Article

Download full-text PDF

Source
December 2018
3 Reads

Corneal dysplastic melanosis associated with recurrent corneal erosions: A case report.

Medicine (Baltimore) 2018 Dec;97(51):e13367

Department of Ophthalmology, Seoul National University College of Medicine.

Rationale: Pigmented lesions of conjunctiva and cornea can be observed in various conditions, from the benign nevus to malignant melanoma. Pigmented acquired melanosis (PAM) is one of them, which is a neoplastic proliferation with malignant transformation potential of melanocytes. However, to our knowledge, there has been no report as to a disturbance of corneal barrier function caused by PAM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319972PMC
December 2018
7 Reads

Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAF Mutation-Positive Metastatic Malignancy.

Clin Pharmacol Drug Dev 2018 Dec 20. Epub 2018 Dec 20.

Genentech, Inc., South San Francisco, CA, USA.

Vemurafenib prolongs survival in patients with BRAF -mutated advanced melanoma. In vitro studies show cytochrome P450 (CYP) 3A4 is involved in vemurafenib metabolism, but the effect of strong inducers or inhibitors of CYP3A4 on vemurafenib exposure in vivo is unknown. This phase 1, open-label, multicenter study evaluated the effect of rifampicin, a CYP3A4 inducer, on the pharmacokinetics of single-dose vemurafenib in 27 patients with BRAF mutation-positive metastatic malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpdd.643DOI Listing
December 2018
3 Reads

Glaucoma secondary to intraocular tumors: mechanisms and management.

Curr Opin Ophthalmol 2019 Mar;30(2):71-81

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.

Purpose Of Review: Glaucoma secondary to intraocular tumors is important to consider in eyes with a known tumor and those with unilateral or refractory glaucoma. The purpose of this review is to discuss the mechanisms and management of intraocular tumors with related secondary glaucoma.

Recent Findings: Several intraocular tumors can lead to glaucoma, including iris melanoma, iris metastasis, iris lymphoma, trabecular meshwork melanoma, choroidal melanoma, choroidal metastasis, retinoblastoma, and medulloepithelioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICU.0000000000000550DOI Listing
March 2019
7 Reads

Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates.

J Control Release 2019 Jan 13;294:176-184. Epub 2018 Dec 13.

MediaPharma s.r.l., Via della Colonnetta 50/A, 66100 Chieti, Italy. Electronic address:

Galectin-3-binding protein (Gal-3BP) has been identified as a cancer and metastasis-associated, secreted protein that is expressed by the large majority of cancers. The present study describes a special type of non-internalizing antibody-drug-conjugates that specifically target Gal-3BP. Here, we show that the humanized 1959 antibody, which specifically recognizes secreted Gal-3BP, selectively localized around tumor but not normal cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2018.12.018DOI Listing
January 2019
1 Read

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials.

J Clin Med 2018 Dec 12;7(12). Epub 2018 Dec 12.

Department of Medical, Oral and Biotechnological Sciences and CeSI-MeT, G. D'Annunzio University, 66100 Chieti, Italy.

Evidence has recently emerged on the influence of gender on the immune system. In this systematic review and meta-analysis of phase III randomized clinical trials (RCTs), we explored the impact of gender on survival in patients with advanced cancer treated with immune checkpoint inhibitors (ICIs). We performed a comprehensive search of the literature updated to April 2018, including the Cochrane Central Register of Controlled Trials, PubMed, and EMBASE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm7120542DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306894PMC
December 2018

Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report.

Head Neck 2019 Feb 7;41(2):E26-E29. Epub 2018 Dec 7.

Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.

Background: Malignant melanomas on skin graft recipient sites are rare, with few cases reported in the literature.

Methods: We present a case report of a patient with recurrent cutaneous melanoma in the grafted anterolateral thigh flap of the tongue.

Results: A patient underwent hemiglossectomy with free flap reconstruction for squamous cell carcinoma of the tongue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.25417DOI Listing
February 2019
12 Reads

Hypercellular Encapsulated Neuroma Imitating Desmoplastic Melanoma.

Am J Dermatopathol 2018 Nov 22. Epub 2018 Nov 22.

Department of Pathology, University of Washington School of Medicine, Seattle, WA.

Palisaded encapsulated neuromas (PENs) are benign cutaneous nerve sheath proliferations that typically occur as flesh-colored papules solitarily on the head and neck in adults, with a slight predilection for females. Histopathologically, they are partially or completely encapsulated intradermal nodules with Schwann cells and axons in fascicles separated by clefts. Although these features are often characteristic, the hypercellular variant of PEN can pose a diagnostic challenge in distinguishing between other cellular neural and melanocytic lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001302DOI Listing
November 2018
2 Reads

The existence of early stage oral mucosal melanoma: A 10-year retrospective analysis of 170 patients in a single institute.

Oral Oncol 2018 Dec 24;87:70-76. Epub 2018 Oct 24.

Dept. of Oral & Maxillofacial - Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai 200011, China. Electronic address:

Background: Oral mucosal melanoma (OMM) is an aggressive tumor with an extremely low incidence, and the current TNM Staging System has classified all OMMs as high stage. However, controversy remains regarding the existence of early stage OMMs.

Patients And Methods: The clinical and pathological features, treatments and outcomes of 170 OMM patients treated in a single institution from January 2007 to July 2017 were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2018.10.022DOI Listing
December 2018

Incidence of non-melanoma skin cancer in patients treated with psoralen and ultraviolet A therapy.

Med Clin (Barc) 2018 Nov 29. Epub 2018 Nov 29.

Servicio de Dermatología, Hospital General Universitario de Valencia, Valencia, España; Facultad de Medicina, Universitat de València, Valencia, España.

Introduction: Studies reporting incidences of non-melanoma skin cancer (NMSC) are heterogeneous, depend on the geographic area of the studied population and are often short-term. The aim of this study is to determine the incidence of NMSC in patients treated with oral PUVA therapy in the Mediterranean area.

Material And Methods: A retrospective, observational study was carried out with a sample of 234 patients treated with systemic PUVA between 1982 and 1996, carrying out a historical follow-up until May 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2018.09.018DOI Listing
November 2018
2 Reads

Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology.

BMC Cancer 2018 Dec 4;18(1):1219. Epub 2018 Dec 4.

OCR (Oncovet Clinical Research), SIRIC ONCOLille, Parc Eurasante, Rue du Dr Alexandre Yersin, F-59120, Loos, France.

Background: Metastatic melanoma is one of the most aggressive forms of cancer in humans. Among its types, mucosal melanomas represent one of the most highly metastatic and aggressive forms, with a very poor prognosis. Because they are rare in Caucasian individuals, unlike cutaneous melanomas, there has been fewer epidemiological, clinical and genetic evaluation of mucosal melanomas. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-018-5114-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280433PMC
December 2018
7 Reads

Data Set for Reporting of Mucosal Melanomas of the Head and Neck: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting.

Arch Pathol Lab Med 2018 Nov 30. Epub 2018 Nov 30.

From the Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston (Dr Williams); the Department of Translational Research, University of Pisa, Pisa, Italy (Dr Franchi); the Department of Pathology, University of Liverpool, Liverpool, United Kingdom (Dr Helliwell); Atlanta Oral Pathology, Decatur, Georgia (Dr Müller); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills (Dr Thompson).

Standardized pathologic reporting for cancers allows for improved communication for patient care and prognostic determination. If used universally, synoptic reporting enhances comparing data globally for scientific leverage. The International Collaboration on Cancer Reporting is a nonprofit organization whose mission is to develop evidence-based, universally available surgical pathology reporting data sets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0412-SADOI Listing
November 2018

Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review.

Melanoma Res 2018 Nov 26. Epub 2018 Nov 26.

Departments of Dermatology.

Nivolumab is widely used to treat several late-stage malignancies such as melanoma and non-small-cell lung cancer by inhibiting the interaction between the programmed cell death protein-1 and its ligand. By stimulating an antitumor immune response, it also leads to immune adverse events. Here. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000536DOI Listing
November 2018
1 Read

Diffusion-weighted magnetic resonance imaging in oral and maxillofacial lesions: preliminary study on diagnostic ability of apparent diffusion coefficient maps.

Oral Radiol 2018 Sep 4;34(3):224-228. Epub 2017 Sep 4.

Department of Radiology, The Nippon Dental University Niigata Hospital, 1-8 Hamaura-cho, Chuo-ku, Niigata, Niigata, 951-8580, Japan.

Objectives: The aim of this study was to investigate the usefulness of diffusion-weighted magnetic resonance imaging (DWI) in oral and maxillofacial lesions, especially the utility of apparent diffusion coefficient (ADC) maps for differential diagnosis of these lesions.

Methods: Fifty-seven patients who underwent magnetic resonance imaging for diagnosis of oral and maxillofacial lesions were included in this prospective study. DWI was performed on a 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11282-017-0303-yDOI Listing
September 2018
7 Reads

Molecular and immunohistochemical analyses of uveal melanoma patient cohort.

Melanoma Res 2018 Nov 21. Epub 2018 Nov 21.

Departments of Surgery.

Uveal melanoma is a rare form of melanoma and the most frequent primary eye malignancy in adults. The major molecular alterations underlying uveal melanoma pathogenesis affect mainly the GNAQ, GNA11, SF3B1, and BAP1 genes. In this study, we somatically genotyped 31 Brazilian uveal melanomas for BRAF, GNA11, GNAQ, SF3B1, and BAP1 gene mutations and assessed BRCA2 and p53 protein expression. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00008390-900000000-9921
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000523DOI Listing
November 2018
7 Reads

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.

Clin Gastroenterol Hepatol 2018 Nov 23. Epub 2018 Nov 23.

Pfizer Inc, Collegeville, Pennsylvania.

Background & Aims: Tofacitinib is an oral, small-molecule inhibitor of JAK approved in several countries for the treatment of ulcerative colitis (UC). We report integrated safety analyses of tofacitinib-treated patients with moderate to severe UC.

Methods: Patients receiving placebo or tofacitinib (5 or 10 mg) twice daily were analyzed as 3 cohorts: induction (phase 2 and 3 induction studies, n = 1220), maintenance (phase 3 maintenance study, n = 592), and overall (patients receiving tofacitinib 5 or 10 mg twice daily in phase 2, phase 3, or open-label, long-term extension studies, n = 1157; 1613 patient-years' exposure). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2018.11.035DOI Listing
November 2018
2 Reads